RMD Stock Recent News
RMD LATEST HEADLINES
ResMed achieved double-digit revenue and profit growth over the past 9 years, driven by continuous acquisitions and improving operating efficiencies. ResMed's capital efficiencies showed mixed results, with improvements in gross profitability and asset turnover but a longer cash conversion cycle. But there were improving returns. The company is financially sound. There is a margin of safety if you assume that there would be another major acquisition next year.
Major U.S. equities indexes ended lower on Wednesday after the Federal Reserve reduced its benchmark interest rate by half a percentage point. Central bank policymakers opted for an aggressive rate cut as the focus shifts toward economic growth and the employment market following a multi-year campaign to fight inflation.
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online.
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "U.S. Sleep Disorders Treatment Market: Sleep Centers, Sleep Studies & CPAPs" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY.
SAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed's regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed's directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed's board audit committee.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NEW YORK, NY / ACCESSWIRE / August 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.
Leading respiratory care device maker ResMed Inc. (RMD) is a profit producing machine.